- Cleveland BioLabs (NASDAQ:CBLI): Q1 GAAP EPS of -$0.08.
- Revenue of $0.2M (-13.0% Y/Y)
- Press Release
- More news on: Cleveland BioLabs, Inc., Earnings news and commentary, Consumer stocks news, ,
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Cytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc." New Corporate Name and Updated Stock Ticker Symbol to Showcase Company's Post-Merger Transformation and Focus on Restoring Immune Health PR Newswire FORT COLLINS, Colo. , Aug. 31...
Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via Webcast Audio archive for the event may be accessed from the "Investors" section of the Cytocom website PR Newswire FORT COLLINS, Colo. , Aug. 16, 2021 /PRNewswire/ -- ...
Cytocom, Inc. Reports Second Quarter 2021 Financial Results -All-stock merger transaction between legacy Cleveland BioLabs and legacy Cytocom recently completed; Cytocom, Inc. common stock trading on Nasdaq as "CBLI"- -Well financed allowing multiple clinical programs that c...